NCT00902200

A Study of AR-12286 in Patient With Elevated Intraocular Pressure (IOP)

A Phase 2, Double-masked, Randomized, Placebo-controlled, Dose-response Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 Ophthalmic Solution 0.05%, 0.1% and 0.25% in Patients With Elevated Intraocular Pressure

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 89 (actual)
• Sponsor: Aerie Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Double-masked, randomized, multi-center, placebo-controlled parallel-comparison of AR-12286.

Detailed description

Subjects will be randomized to receive AR-12286 Ophthalmic Solution 0.05%, 0.1%, and 0.25% or its vehicle (one eye), q.d. (AM) x 7 days, then q.d. (PM) x 7 days, then b.i.d. x 7 days. The first dose will be administered in the clinic. Ocular safety and ocular hypotensive efficacy will be evaluated in the clinic throughout this period.

Conditions

• Elevated Intraocular Pressure

Interventions

Type	Name	Description
DRUG	AR-12286	See arms
DRUG	AR-12286 vehicle	See arms

Timeline

• Start date: 2009-05-01
• Primary completion: 2009-09-01
• Completion: 2009-09-01
• First posted: 2009-05-15
• Last updated: 2014-04-21

Locations

8 sites across 1 country: United States